Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase NA 3Phase 3 3Phase 1 3Phase EARLY_PHASE1 2Phase 1/2 2Phase 2/3 1

Status

Suspended 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Breast 1

Conditions

Neoplasms 1Breast Neoplasms 1

Interventions

pembrolizumab 35Carboplatin 24Specimen Handling 20Cyclophosphamide 19Magnetic Resonance Spectroscopy 18fludarabine 15Dexamethasone 15Nivolumab 14Gemcitabine 14Bevacizumab 14Biopsy 12atezolizumab 11Temozolomide 11Paclitaxel 10Docetaxel 10Cisplatin 10venetoclax 9Rituximab 9Pemetrexed 9Ipilimumab 9Prednisone 8Lenalidomide 8Fluorouracil 8blinatumomab 7Vincristine 7Radiotherapy 7Oxaliplatin 7Capecitabine 7olaparib 6lenvatinib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Fluorodeoxyglucose F18 × 30 days × Clear all
NCT06502691 2026-05-19

[18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic Breast Cancer

University of Washington

Phase 1/2 Recruiting
22 enrolled
Breast

Breast Neoplasms

NCT02130492 2026-05-15

A Pilot Study Treatment of Malignant Tumors Using [18F] Fluorodeoxyglucose (FDG)

Weill Medical College of Cornell University

Phase 1/2 Suspended
30 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡